|1.||Verstovsek, Srdan: 13 articles (12/2013 - 11/2005)|
|2.||Tefferi, Ayalew: 10 articles (04/2015 - 08/2005)|
|3.||Vainchenker, William: 7 articles (08/2013 - 06/2006)|
|4.||Prchal, Josef T: 6 articles (07/2015 - 11/2005)|
|5.||Cazzola, Mario: 6 articles (06/2014 - 11/2005)|
|6.||Kralovics, Robert: 5 articles (06/2014 - 11/2005)|
|7.||Funakoshi-Tago, Megumi: 5 articles (11/2013 - 05/2011)|
|8.||Green, Anthony R: 4 articles (02/2015 - 10/2009)|
|9.||Guglielmelli, Paola: 4 articles (02/2015 - 08/2009)|
|10.||Barbui, Tiziano: 4 articles (02/2015 - 08/2007)|
07/01/2015 - "Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm."
12/01/2014 - "The aim of this study was to investigate the presence of Janus kinase 2 (JAK2) V617F mutation in patients with break point cluster region-abelson negative chronic myeloproliferative neoplasms (CMPNs) in our center. "
11/01/2012 - "This study evaluated potential correlations between the allele burden of the Janus kinase 2 (JAK2) V617F mutation and clinicohematologic characteristics in patients with myeloproliferative neoplasms (MPN). "
11/01/2010 - "Although clinical trials of the much anticipated small molecule inhibitors of Janus kinase 2 have shown that these experimental agents are successful in palliating many of the symptoms associated with the myeloproliferative neoplasms, they have not been reported to affect the disease initiating hematopoietic stem cell population or to alter the natural history of these disorders. "
09/01/2008 - "The objective of this study was to validate the recently revised 2008 WHO diagnostic criteria of myeloproliferative neoplasms (MPN) together with the analysis of correlation of JAK2 (Janus kinase 2)-V617F mutant allele burden with clinical/laboratory findings on each patient. "
|2.||Primary Myelofibrosis (Myelosclerosis)
01/01/2015 - "We conducted an exploratory analysis of sequential BMF data from two phase I studies of long-term treatment with the Janus kinase 2 (JAK2) inhibitor fedratinib in patients with myelofibrosis. "
12/01/2015 - "We report an extremely rare case of a female child who presented the onset of primary myelofibrosis (PMF) harboring JAK2 (Janus Kinase 2 gene) mutation (JAK2V617F) when she was 15months old. "
01/01/2014 - "In 2005, the discovery of Janus kinase 2 (JAK2) V617F mutation in approximately half of patients with myelofibrosis (MF) marked an important milestone in our understanding of the pathophysiology of MF. "
03/01/2013 - "What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?"
09/16/2010 - "About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiology of the disease. "
12/01/2010 - "Reply: Blockade of Janus kinase 2 signaling ameliorates mouse liver damage due to ischemia and reperfusion."
09/01/2010 - "Blockade of Janus kinase 2 signaling ameliorates mouse liver damage due to ischemia and reperfusion."
05/01/2011 - "Activation of the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3) pathway is known to play a key role in cardiogenesis and to afford cardioprotection against ischemia-reperfusion in adult. "
03/01/2013 - "This review discusses the pathogenesis of thrombosis of mesenteric veins, the diagnosis and differentiation from arterial ischemia, the emergence of the JAK2 (Janus kinase 2) sequence variation as a marker of thrombophilia and myelodysplastic neoplasms, and new anticoagulants. "
06/01/2006 - "G-CSF strongly activated Janus kinase 2 (Jak2), STAT3, extracellular signal-regulated kinase (ERK), Akt, and endothelial NO synthase (NOS) in the hearts subjected to ischemia followed by 15-minute reperfusion. "
|4.||Myeloproliferative Disorders (Myeloproliferative Disorder)
08/27/2009 - "Ongoing clinical trials of Janus kinase 2 (JAK2) inhibitors in myeloproliferative disorder patients use small molecules targeting both wild-type and mutated JAK2. "
06/01/2015 - "Herein we report a rapid, accurate and robust UHPLC-MS/MS assay for the quantitation of BMS-911453, a Janus kinase 2 inhibitor under clinical development for the treatment of myeloproliferative disorders, in human plasma. "
02/15/2014 - "Janus Kinase 2 (JAK2) gene single point mutations, which have been reported to be associated with myeloproliferative disorders, are usually detected through conventional methods such as melting curve assays, allele-specific and quantitative Polymerase Chain Reactions (PCRs). "
09/01/2012 - "An activating mutation of Janus kinase 2 (JAK2-V617F) was previously described in chronic myeloproliferative disorders (MPD). "
02/01/2012 - "Janus kinase 2 (JAK2) V617F mutation testing has revolutionized the classification of myeloproliferative disorders, for which several tests have been introduced for qualitative and quantitative diagnostics including the MutaScreen and MutaQuant kits by IPSOGEN. "
|5.||Breast Neoplasms (Breast Cancer)
01/01/2015 - "We validated that Janus kinase 2 (JAK2), as a direct target of miR-204, is overexpressed in breast cancer. "
01/01/2014 - "miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2."
06/01/2007 - "Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer."
02/01/2010 - "In this study, we for the first time report that OPN upregulates alphavbeta3 integrin-mediated Janus kinase 2 (JAK2) phosphorylation and STAT3 activation in breast cancer (MDA-MB-468 and MCF-7) cells. "
09/15/2014 - "The objective of this study was to investigate the enhancement of CEP-33779, a small-molecule inhibitor of Janus kinase 2 (JAK2), on the efficacy of conventional chemotherapeutic agents in MDR cells with overexpression of P-glycoprotein (ABCB1), multidrug resistance-associated protein 1 (ABCC1) and breast cancer resistance protein (ABCG2). "
|2.||Messenger RNA (mRNA)
|4.||multidrug resistance-associated protein 1
|6.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|7.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|8.||Interleukin-6 (Interleukin 6)
|10.||Protein Kinases (Protein Kinase)
|1.||Stem Cell Transplantation
|2.||Heterologous Transplantation (Xenotransplantation)
|5.||Transplantation (Transplant Recipients)